| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5616334 | LEADIANT BIOSCI INC | Low toxicity drug-lipid systems |
Apr, 2014
(10 years ago) | |
| US6406713 | LEADIANT BIOSCI INC | Methods of preparing low-toxicity drug-lipid complexes |
Jun, 2019
(4 years ago) | |
Abelcet is owned by Leadiant Biosci Inc.
Abelcet contains Amphotericin B.
Abelcet has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Abelcet are:
- US5616334
- US6406713
Abelcet was authorised for market use on 20 November, 1995.
Abelcet is available in injectable, lipid complex;injection dosage forms.
The generics of Abelcet are possible to be released after 18 June, 2019.
Drugs and Companies using AMPHOTERICIN B ingredient
Market Authorisation Date: 20 November, 1995
Treatment: NA
Dosage: INJECTABLE, LIPID COMPLEX;INJECTION
More Information on Dosage
ABELCET family patents
